Discovery Research In Japan By Global Pharmas: Evolving More Toward Partnerships? (Part 1 of 3)
This article was originally published in The Pink Sheet Daily
Executive Summary
While some globe-spanning pharmaceutical companies are maintaining or increasing their investment in discovery research in Japan, many more are moving in the opposite direction.
You may also be interested in...
Banyu to Close Tsukuba Lab as Part of Merck’s Global Research Revamp
TOKYO - Merck subsidiary Banyu Pharmaceutical, said Oct. 23 it would close its research laboratory in Tsukuba City, northeast of Tokyo, by the end of 2009, leaving only a fraction of foreign drug makers with basic research activities in Japan
Pfizer Head of R&D Business Development – Asia Alex Fowkes On Matching Global Partners With Pfizer’s Pipeline: An Interview With PharmAsia News (Part 2 of 2)
Pfizer's Head of R&D Business Development - Asia Alex Fowkes sat down with PharmAsia News' Australia bureau to discuss Pfizer's business development and research strategies in Asia. Fowkes recently addressed a panel at the BioAsia conference in Singapore and discussed Pfizer's virtual approach to doing business in Asia, which offers more flexibility and creative approaches (PharmAsia News, May 8, 2008).
Pfizer Avoids Japan R&D Layoffs With Creation Of New Business
Pfizer is spinning off some of its Nagoya, Japan, research site into a venture-backed start-up called RaQualia Pharma Inc., the company reported July 3